Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Going Concern and Plan of Operation (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ 11,007,441		$ 11,007,441		$ 3,830,719
Net loss	$ 2,611,828	$ 1,456,343	$ 7,176,723	$ 1,911,790

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.